Santhera Pharmaceuticals Holding AG at HC Wainwright Investment Conference - New York Transcript
Good morning. Thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Oren Livnat, specialty pharmaceuticals analyst here at H.C. Wainwright. It's my pleasure to welcome our next presenter, Dario Eklund, CEO of Santhera Pharmaceuticals, Swiss specialty pharmaceutical company focused on rare neuromuscular and pulmonary diseases with its lead asset having a very near-term October PDUFA date. Sounds quite exciting, so I look to hearing more.
Please take it away, Dario.
Thank you, Oren, and thank you to H.C. Wainwright for inviting us to speak today. I'm excited to be here because we're getting very close to an inflection point with the mentioned FDA PDUFA date. First, I'd like to start with a greeting from our legal department. I will be making forward-looking statements during this presentation.
So as already mentioned, we're a Swiss-based company. I'll cover a little bit of background on the company
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |